VG-3927

TargetTREM2

Modalitysmall molecule agonist

IndicationAlzheimer's disease

PhasePhase 1 (Completed)

PartnerNone

Trial IDNCT06343636

Notes

VG-3927 is a highly brain-penetrant, first-in-class small molecule TREM2 agonist designed to activate microglia in Alzheimer's disease. Phase 1 trials evaluate safety, pharmacokinetics, and pharmacodynamics in healthy volunteers.

Source

Program entries are factual summaries of publicly disclosed clinical programs. Microglia.ai does not imply predictions about therapeutic outcomes or investment advice.

Last reviewed: June 2, 2026